1. Home
  2. |Insights
  3. |Biosimilars Conference

Biosimilars Conference

Event | 11.18.09 - 11.19.09, 12:00 AM UTC - 12:00 AM UTC

With 20 speakers confirmed, this year’s Biosimilars conference is set to be jam-packed. Don’t miss the chance to:

  • Explore the latest developments in the US. What are the upcoming futures and challenges?
  • Revisit the EU Market. Learn what the growth drivers and restraints have been and what products to look out for
  • Evaluate the market from an innovator, biosimilar and dual perspective with presentations from Roche Pharma Research, Intas Pharmaceuticals and Merck Bioventures
  • Discover recent developments and comparability approaches to biosimilar mAbs. Learn the challenges and regulatory requirements that must be considered
  • Update your knowledge on advancements in biosimilar comparability, immunogenicity, formulation and pharmacokinetics
  • Analyse regulatory expectations on a Global basis and discover further information on development costs and the potential future impact in emerging markets
  • Ascertain what the payer’s perception is of the biosimilar market and the pricing and access environment for biosimilars
  • Familiarise yourself with patent law strategies and the ones to watch out for

Kristof Roox will speak about "Application of patent litigation strategies to biosimilars: is there a difference?".

Insights

Event | 12.04.25

ACI 30th Annual Conference on Drug & Medical Device Litigation

Dan Campbell with Speak on the panel "Mastering MDL Case Management: What Proposed Rule 16.1 Really Means for Consolidated Litigation."
Rule 16.1 attempts to guide early case management in MDLs, impacting litigation pace and costs. Permissive language like “should” instead of “must”, could lead to inconsistent applications. This panel will explore the rule’s anticipated impact and implications for procedures.